Management expressed confidence in sustaining revenue and bottom-line growth in 2025, despite residual impacts of VYVANSE's genericization. For the first nine months of FY 2024, Takeda reported ...

The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions. Takeda ...

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...

The appointment comes as Takeda sees a competitive growth outlook with new product launches from the second half of 2026, Weber said in a statement. “Now is the right time,” he said ...

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. | Takeda has named Julie Kim ...